Literature DB >> 19212116

Controversies in the use of portal vein embolization.

Thomas M van Gulik1, Jacomina W van den Esschert, Wilmar de Graaf, Krijn P van Lienden, Olivier R C Busch, Michal Heger, Otto M van Delden, Johan S Laméris, Dirk J Gouma.   

Abstract

BACKGROUND/AIMS: Portal vein embolization (PVE) has reached worldwide acceptance to increase future remnant liver (FRL) volume before undertaking major liver resection. The aim of this overview is to point out and discuss current controversies in the application of PVE.
METHODS: Review of literature pertaining to techniques of PVE, complications, tumor proliferation, timing of resection, and hypertrophy response after PVE.
RESULTS: Procedure-related complications after PVE include hematoma, hemobilia, overflow of embolization material, and thrombosis of portal vein branch(es) of the non-embolized lobe. Persistence of the embolized, atrophic lobe is usually not harmful. Embolization of the portal branches to segment 4 in addition to embolization of the right portal trunk is controversial and is advised only in selected cases. It remains undecided whether embolization of the portal venous system is more effective in inducing hypertrophy of the FRL than ligation of the portal vein. Accelerated tumor growth after PVE is a major concern and requires consideration of post-PVE chemotherapy. A waiting time of 3 weeks between PVE and liver resection is advised. Post-hepatectomy regeneration is not hampered after preoperative PVE.
CONCLUSION: PVE is a useful preoperative intervention to increase volume and function of the FRL. Further progress awaits clarification of the mechanisms of the hypertrophy response induced by PVE in conjunction with new embolization materials and protective chemotherapy. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19212116     DOI: 10.1159/000184735

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  25 in total

1.  Partial hepatectomy improves the outcome of intraportal islet transplantation by promoting revascularization.

Authors:  Yukihiko Saito; Nathaniel K Chan; Eba Hathout
Journal:  Islets       Date:  2012-03-01       Impact factor: 2.694

Review 2.  Staged resection of bilobar colorectal liver metastases: surgical strategies.

Authors:  Cui Yang; Nuh N Rahbari; Sören Torge Mees; Felix Schaab; Moritz Koch; Jürgen Weitz; Christoph Reissfelder
Journal:  Langenbecks Arch Surg       Date:  2015-06-08       Impact factor: 3.445

3.  Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.

Authors:  Nerea Fernández-Ros; Nuno Silva; Jose Ignacio Bilbao; Mercedes Iñarrairaegui; Alberto Benito; Delia D'Avola; Macarena Rodriguez; Fernando Rotellar; Fernando Pardo; Bruno Sangro
Journal:  HPB (Oxford)       Date:  2013-03-27       Impact factor: 3.647

Review 4.  Portal vein embolization effect on colorectal cancer liver metastasis progression: Lessons learned.

Authors:  Eman Al-Sharif; Eve Simoneau; Mazen Hassanain
Journal:  World J Clin Oncol       Date:  2015-10-10

5.  Laparoscopic Central Bisectionectomy and Right Anterior Sectionectomy Using Two Retraction Methods: Technical Aspects with Video.

Authors:  Il Han Jeung; Sung Hoon Choi; Seungki Kim; Sung Won Kwon
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

6.  Operable malignant jaundice: To stent or not to stent before the operation?

Authors:  Rungsun Rerknimitr; Pinit Kullavanijaya
Journal:  World J Gastrointest Endosc       Date:  2010-01-16

7.  Tumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation.

Authors:  Jens Sperling; Christian Ziemann; Anika Gittler; Anna Benz-Weißer; Michael D Menger; Otto Kollmar
Journal:  Clin Exp Metastasis       Date:  2015-02-19       Impact factor: 5.150

8.  Surgical strategies in patients with advanced hilar cholangiocarcinoma (Klatskin tumor).

Authors:  J R Izbicki; T Y Tsui; B A Bohn; M Bockhorn
Journal:  J Gastrointest Surg       Date:  2012-12-14       Impact factor: 3.452

9.  Clinical feasibility of inferior right hepatic vein-preserving trisegmentectomy 5, 7, and 8 (with video).

Authors:  Sung Hoon Choi; Gi Hong Choi; Dai Hoon Han; Jin Sub Choi; Woo Jung Lee
Journal:  J Gastrointest Surg       Date:  2013-01-29       Impact factor: 3.452

10.  How we do it: double in situ split for staged mesohepatectomy in patients with advanced gall bladder cancer and marginal future liver remnant.

Authors:  Tung Yu Tsui; Asmus Heumann; Yogesh K Vashist; Jakob R Izbicki
Journal:  Langenbecks Arch Surg       Date:  2016-03-30       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.